Histological regression in primary melanoma: Not a predictor of sentinel lymph node metastasis in a cohort of 397 patients

British Journal of Dermatology

Volumn 162, Issue 4, 2010, Pages 830-834

  Socrier, Y ^a,b   Lauwers Cances, V ^a,b   Lamant, L ^a,b   Garrido, I ^c   Lauwers, F ^a,b   Lopez, R ^a,b   Rochaix, P ^c   Chevreau, C ^c   Payoux, P ^a,b   Viraben, R ^a,b   Paul, C ^a,b   Meyer, N ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b CHU PURPAN   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Histological regression; Melanoma; Sentinel lymph node

Indexed keywords

ADULT; ARTICLE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; SKIN ULCER; TUMOR REGRESSION; AGED; CHI SQUARE DISTRIBUTION; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; SECONDARY; SKIN TUMOR; TUMOR RECURRENCE;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM REGRESSION, SPONTANEOUS; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 77949790738     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09606.x     Document Type: Article

References (22)

1. Liszkay G, Orosz Z, Peley G et al. Relationship between SLN status and regression of primary malignant melanoma. Melanoma Res 2005 15 : 509 513.
2. Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma. Cancer 1978 42 : 2282 2292.
3. Guitart J, Lowe L, Piepkorn M et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol 2002 138 : 603 608.
4. Cook MG, Spatz A, Bröcker EB, Ruiter DJ. Identification of histological features associated with metastatic potential in thin (< 1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC melanoma group. J Pathol 2002 197 : 188 193.
5. Tefany FJ, Barnetson R, Halliday GM et al. Immunohistochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 1991 97 : 197 202.
6. Topalian SL, Salomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989 142 : 3714 3725.
7. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol 1996 8 : 628 636.
8. Shaw HM, McCarthy SW, McCarthy WH et al. Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases. Histopathology 1989 15 : 257 265.
9. Cecchi R, Pavesi M, Buralli L et al. Tumour regression does not increase the risk of sentinel node involvement in thin melanomas. Chir Ital 2008 60 : 257 260.
10. Trau H, Kopf AW, Rigel DS et al. Regression in malignant melanoma. J Am Acad Dermatol 1983 8 : 363 368.
11. Kelly JW, Sagebiel RW, Blois MS. Regression in malignant melanoma. A histologic feature without independent prognostic significance. Cancer 1985 56 : 2287 2291.
12. Kaur M, Thomas RJ, Desai M et al. The correlation of regression in primary melanoma with SLN status. J Clin Pathol 2008 61 : 297 300.
13. Alquier-Bouffard A, Franck F, Joubert-Zakeyh J et al. Regression in primary cutaneous melanoma is not predictive for sentinel lymph node micrometastasis. Ann Dermatol Venereol 2007 134 : 521 525.
14. Olah J, Gyulai R, Korom I et al. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol 2003 149 : 662 663.
15. Naruns PL, Nizze JA, Cochran AJ et al. Recurrence potential in thin melanomas. Cancer 1986 57 : 545 548.
16. Slingluff CL Jr., Vollmer RT, Reintgen DS, Seigler HF. Lethal 'thin' malignant melanoma. Identifying patients at risk. Ann Surg 1988 208 : 150 161.
17. Morton DL, Thompson JF, Cochran AJ et al., MSLT Group. Sentinel node biopsy or nodal observation in melanoma. N Engl J Med 2006 355 : 1307 1317.
18. Mackie RM, Byrne D, Lyngam MK et al. Prognostic evaluation of sentinel node biopsy. Melanoma Res 1992 7 : S102.
19. Gershenwald JE, Thompson W, Mansfield PF et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel node status in 612 stage I or II melanoma patients. J Clin Oncol 1999 17 : 976 983.
20. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001 19 : 3635 3648.
21. Elder DE, Murphy GF. Melanocytic Tumors of the Skin. Washington, DC : Armed Forces Institute of Pathology, 1991 163 164.
22. Pages C, Rochaix P, Al Saati T et al. KBA.62: a useful marker for primary and metastatic melanoma. Hum Pathol 2008 39 : 1136 1142.